IPO Update: bioAffinity Technologies Readies $10 Million IPO

Summary

  • bioAffinity Technologies has filed proposed terms for a $10 million IPO.
  • The firm is developing diagnostics tests, including its lead test for detection of lung cancer.
  • BIAF is still a long way from possible marketing approval for its lead test, so I'm on Hold for the IPO.
  • Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More »

Doctor listening to patient"s heartbeat during home visit - wearing face mask

FG Trade/E+ via Getty Images

A Quick Take On bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF) (BIAFW) intends to raise $10 million from the sale of its common stock and warrants in an IPO, according to an amended registration statement.

The company

Statement of Operations

Statement of Operations (SEC EDGAR)

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis.

Get started with a free trial!

This article was written by

Donovan Jones profile picture
18.83K Followers
Author of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Investing in new issues can be a volatile and opaque endeavor. My research is focused on identifying quality companies at a reasonable price, but I’m wrong sometimes. I analyze fundamental company performance and my conclusions may not be relevant for first-day or early new issue trading activity, which can be highly volatile and unrelated to company fundamentals. This report is intended for educational purposes only and is not financial, legal or investment advice. The information referenced or contained herein may change, be in error, become outdated and irrelevant, or removed at any time without notice. You should perform your own research for your particular financial situation before making any decisions. Investing in new issues is subject to significant volatility and risk of loss.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.